Literature DB >> 11877469

Short-circuiting long-lived humoral immunity by the heightened engagement of CD40.

Loren D Erickson1, Brigit G Durell, Laura A Vogel, Brian P O'Connor, Marilia Cascalho, Teruhito Yasui, Hitoshi Kikutani, Randolph J Noelle.   

Abstract

Agonistic alpha CD40 Ab's have been shown to be potent immune adjuvants for both cell- and humoral-mediated immunity. While enhancing short-lived humoral immunity, the administration of a CD40 agonist during thymus-dependent immune responses ablates germinal center formation, prematurely terminates the humoral immune response, blocks the generation of B cell memory, and prevents the generation of long-lived bone marrow plasma cells. Interestingly, some of these effects of heightened CD40 engagement could be mimicked by enhancing the magnitude of antigen-specific T cell help. Taken together, these studies demonstrate that as the magnitude of CD40 signaling intensifies, the fate of antigen-reactive B cells can be dramatically altered. These are the first studies to describe the multifaceted function of CD40 in determining the fate of antigen-reactive B cells and provide novel insights into how CD40 agonists can short-circuit humoral immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877469      PMCID: PMC150892          DOI: 10.1172/JCI14110

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process.

Authors:  C Mauri; L T Mars; M Londei
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

Authors:  R R French; H T Chan; A L Tutt; M J Glennie
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

3.  T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

Authors:  S P Schoenberger; R E Toes; E I van der Voort; R Offringa; C J Melief
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

4.  Humoral immunity due to long-lived plasma cells.

Authors:  M K Slifka; R Antia; J K Whitmire; R Ahmed
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

5.  Lifetime of plasma cells in the bone marrow.

Authors:  R A Manz; A Thiel; A Radbruch
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

6.  Mouse CD38 is down-regulated on germinal center B cells and mature plasma cells.

Authors:  A M Oliver; F Martin; J F Kearney
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

7.  Enhancement of T cell-independent immune responses in vivo by CD40 antibodies.

Authors:  P Dullforce; D C Sutton; A W Heath
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

8.  Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses.

Authors:  J Uchida; T Yasui; Y Takaoka-Shichijo; M Muraoka; W Kulwichit; N Raab-Traub; H Kikutani
Journal:  Science       Date:  1999-10-08       Impact factor: 47.728

9.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

Authors:  S R Bennett; F R Carbone; F Karamalis; R A Flavell; J F Miller; W R Heath
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

10.  In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers.

Authors:  J Jacob; G Kelsoe
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

View more
  46 in total

1.  A genetic lesion that arrests plasma cell homing to the bone marrow.

Authors:  Loren D Erickson; Ling-Li Lin; Biyan Duan; Laurence Morel; Randolph J Noelle
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

2.  Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo.

Authors:  Dimitris Panagopoulos; Panayiotis Victoratos; Maria Alexiou; George Kollias; George Mosialos
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  CD40L-null NKT cells provide B cell help for specific antibody responses.

Authors:  Hemangi B Shah; Sunil K Joshi; Mark L Lang
Journal:  Vaccine       Date:  2011-09-28       Impact factor: 3.641

4.  Constitutive CD40L expression on B cells prematurely terminates germinal center response and leads to augmented plasma cell production in T cell areas.

Authors:  Anna Bolduc; Eugene Long; Dale Stapler; Marilia Cascalho; Takeshi Tsubata; Pandelakis A Koni; Michiko Shimoda
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

5.  Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor.

Authors:  Brian P O'Connor; Laura A Vogel; Weijun Zhang; William Loo; Danielle Shnider; Evan F Lind; Michelle Ratliff; Randolph J Noelle; Loren D Erickson
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 6.  Affinity of antigen encounter and other early B-cell signals determine B-cell fate.

Authors:  Micah J Benson; Loren D Erickson; Michael W Gleeson; Randolph J Noelle
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

7.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

8.  Development of murine lupus involves the combined genetic contribution of the SLAM and FcgammaR intervals within the Nba2 autoimmune susceptibility locus.

Authors:  Trine N Jørgensen; Jennifer Alfaro; Hilda L Enriquez; Chao Jiang; William M Loo; Stephanie Atencio; Melanie R Gubbels Bupp; Christina M Mailloux; Troy Metzger; Shannon Flannery; Stephen J Rozzo; Brian L Kotzin; Mario Rosemblatt; María Rosa Bono; Loren D Erickson
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

Review 9.  The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.

Authors:  Brian P O'Connor; Michael W Gleeson; Randolph J Noelle; Loren D Erickson
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

10.  Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

Authors:  Cory L Ahonen; Anna Wasiuk; Shinichiro Fuse; Mary Jo Turk; Marc S Ernstoff; Arief A Suriawinata; James D Gorham; Ross M Kedl; Edward J Usherwood; Randolph J Noelle
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.